Zilucoplan for Severe gMG Exacerbations
Zilucoplan for Severe gMG Exacerbations
Recruiting · NCT07215949 · Registry updated 2026-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zilucoplan for Severe gMG Exacerbations | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-08-28 | NCT07215949 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Miriam Freimer | 1 |
| UCB Pharma | 15 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Ohio State University | Columbus | United States | 191 |
| University of Kansas Medical Center | Kansas City | United States | 240 |
| University of South Florida/Tampa General Hospital | Tampa | United States | 1 |